Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?

Are we ready to embrace the routine use of immune checkpoint inhibitors in patients with advanced stage non-small-cell lung cancer? In The Lancet, Roy Herbst and colleagues1 report the results of KEYNOTE-010, a randomised phase 2/3 study in 202 academic medical centres in 24 countries that compared two doses of pembrolizumab (2 mg/kg and 10 mg/kg) with docetaxel (75 mg/m2) every 3 weeks in 1034 patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer. This biomarker-enriched study had two primary endpoints of overall survival and progression-free survival both in the total population and in the subgroup of patients with tumour proportion score of 50% or more, which is defined as the percentage of tumour cells expressing PD-L1 assessed by immunohistochemistry using antibody 22C3.